70978-37-9

Usage

Uses

Used in Organic Synthesis:
4-Methoxybenzyl azide is used as a reagent for the introduction of azide groups into molecules, facilitating the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Preparation:
4-Methoxybenzyl azide is utilized as a precursor in the production of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Production:
4-Methoxybenzyl azide is also employed in the synthesis of agrochemicals, playing a role in the creation of pesticides and other agricultural products.
Used in Click Chemistry Reactions:
4-Methoxybenzyl azide is used as a precursor in click chemistry reactions, enabling the efficient and selective production of diverse chemical compounds.
Used in Pharmaceutical and Material Science Industries:
As a building block, 4-Methoxybenzyl azide is crucial in the production of compounds used across the pharmaceutical and material science sectors, supporting the development of innovative materials and therapeutics.

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 2746-25-0 p-Methoxybenzyl bromide 
• 70887-29-5 4-methoxybenzyl iodide 
• 105-13-5 4-Methoxybenzyl alcohol 
• 2393-23-9 4-methoxy-benzylamine 
• 90673-97-5 methanesulfonic acid 4-methoxybenzyl ester 
• 4648-54-8 trimethylsilylazide 
• 104-21-2 p-methoxybenzyl acetate 
• 123-11-5 4-methoxy-benzaldehyde 
• 100-66-3 methoxybenzene 
• 104-93-8 p-methylanizole 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 92567-07-2 1-(diazidomethyl)-4-methoxybenzene 
• 18494-82-1 2-(4-methoxy-benzyloxy)-tetrahydro-pyran 

Downstream Products

• 141072-06-2 methyl 1-(4-methoxybenzyl)-1H-1,2,3-triazole-4-carboxylate 
• 141071-93-4 di-tert-butyl 1-(4-methoxybenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate 
• 79707-03-2 4,9-dihydro-6,7-dimethyl-4,9-dioxo-1-(4-methoxybenzyl)naphtho<2,3-d>-v-triazole 
• 130231-84-4 4-(p-methoxybenzyl)-5-picrylimino-1,2,3,4-thiatriazoline 
• 31794-11-3 1-(p-methoxybenzyl)-1,2,3-triazole 
• 110691-29-7 1-(4-methoxybenzyl)-4,4-bis(ethoxycarbonyl)-5-phenylthio-δ²-1,2,3-triazoline 
• 126799-88-0 dimethyl 1-(4-methoxybenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate 
• 70978-35-7 ethyl 1-(4-methoxybenzyl)-1H-tetrazole-5-carboxylate 
• 81581-08-0 ethyl 1-(4-methoxybenzyl)-4-phenyl-1H-1,2,3-triazole-5-carboxylate 
• 81581-07-9 ethyl 1-(4-methoxybenzyl)-5-phenyl-v-triazole-4-carboxylate 
• 81581-05-7 ethyl 1-(4-methoxybenzyl)-1H-1,2,3-triazole-4-carboxylate 
• 180723-17-5 1-(4-Methoxybenzyl)-1H-1,2,3-triazole-4,5-dicarboxylic acid 
• 79707-02-1 4,9-dihydro-4,9-dioxo-1-(4-methoxybenzyl)naphtho<2,3-d>-v-triazole 
• 120157-94-0 N-(tert-butoxycarbonyl)p-methoxybenzylamine 

Relevant academic research and scientific papers

Regioselectivity in the 1,3-dipolar cycloaddition reactions of nitrile oxides and organic azides with bromocarbazole-1,4-diones

The effect exerted by the presence of a bromine atom in 2 or 3 position of a carbazole-1,4-dione on the regiocontrol of 1,3-dipolar cycloaddition reactions with nitrile oxides and organic azides was investigated. Comparison with the results obtained with

Synthesis and Evaluation of Bakuchiol Derivatives as Potent Anti-inflammatory Agents in Vitro and in Vivo

Bakuchiol, a prenylated phenolic monoterpene derived from the fruit of Psoralen corylifolia L. (Buguzhi), is widely used to treat tumors, viruses, inflammation, and bacterial infections. In this study, we designed and synthesized 30 bakuchiol derivatives

Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents

Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase as the global population ages. Recent studies provide increasing evidence that inflammation plays a key role in the pathogenesis and progression of AD. Diosgenin, an active ingredient in Dioscorea nipponica Makino, is a promising bioactive lead compound in the treatment of Alzheimer's disease, which exhibited anti-inflammatory activity. To search for more efficient anti-Alzheimer agents, a series of novel diosgenin-triazolyl hybrids were designed, synthesized, and their neuroprotective effects against oxygen-glucose deprivation-induced neurotoxicity and LPS-induced NO production were evaluated. Most of these new hybrids displayed better activities than DIO. In particular, the promising compound L6 not only demonstrated an excellent neuroprotective effect but also showed the best anti-inflammatory activity. The structure-activity relationship study illustrated that the introduction of benzyl or phenyl triazole did improve the activity, and the introduction of benzyl triazole was better than that of phenyl triazole. The results we obtained showed that the diosgenin skeleton could be a promising structural template for the development of new anti-Alzheimer drug candidates, and compound L6 has the potential to be an important lead compound for further research.

Synthesis, inhibition properties against xanthine oxidase and molecular docking studies of dimethyl N-benzyl-1H-1,2,3-triazole-4,5-dicarboxylate and (N-benzyl-1H-1,2,3-triazole-4,5-diyl)dimethanol derivatives

This study focused on synthesis various dimethyl N-benzyl-1H-1,2,3-triazole-4,5-dicarboxylate and (N-benzyl-1H-1,2,3-triazole-4,5-diyl)dimethanol derivatives under the conditions of green chemistry without the use of solvent and catalysts. Their inhibition properties were also investigated on xanthine oxidase (XO) activity. All dimethanol and dicarboxylate derivatives exhibited significant inhibition activities with IC50 values ranging from 0.71 to 2.25 μM. Especially, (1-(3-bromobenzyl)-1H-1,2,3-triazole-4,5-diyl)dimethanol (5c) and dimethyl 1-(4-chlorobenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate (6 g) compounds were found to be the most promising derivatives on the XO enzyme inhibition with IC50 values 0.71 and 0.73 μM, respectively. Moreover, the double docking procedure was to evaluate compound modes of inhibition and their interactions with the protein (XO) at atomic level. Surprisingly, the docking results showed a good correlation with IC50 [correlation coefficient (R2 = 0.7455)]. Also, the docking results exhibited that the 5c, 6f and 6 g have lowest docking scores ?4.790, ?4.755, and ?4.730, respectively. These data were in agreement with the IC50 values. These results give promising beginning stages to assist in the improvement of novel and powerful inhibitor against XO.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS

The present disclosure provides processes for preparing 1,2,3-triazole-4-carboxylic acid related compounds of formulae (I) and (II) via a Suzuki coupling reaction. The Suzuki coupling reaction is achieved by coupling a compound of formula (IV), a boron-containing derivative of 1,2,3-triazole-4-carboxylate, with a cycloalkyl phenyl halide or sulfonate of formula (V).

Dipolar HCP materials as alternatives to DMF solvent for azide-based synthesis

Hypercrosslinked polymers HCP-DMF and HCP-DMF-SO3H containing abundant and flexible DMF moieties were designed and synthesized. Benefitting from the solvation microenvironment provided by the pseudo-DMF moities, the polar HCPs manifested outstanding performances in the conversions of NaN3 to benzylic azides and 1,2,3-triazoles in EtOH (95%), respectively, avoiding the use of risky DMF and improving the separation processes of the products.

NOVEL DIBENZOOXAPHOSPHININE OXIDE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE DISEASE COMPRISING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel dibenzooxininin oxide derivative compound having various nitrogen-containing substituents introduced at 6-position of a dibenzooxaphosphorin oxide mononuclear, and to the use thereof. The present invention relates to a pharmaceutical composition for preventing or treating degenerative diseases and a health supplement food composition for preventing or treating degenerative diseases, comprising the dibenzooxaphosphorin oxide derivative compound of the present invention.

Synthesis of new derivatives of alepterolic acid via click chemistry

Alepterolic acid is a natural diterpenoid isolated from Aleuritopteris argentea (S. G. Gmél.) Fée, a fern with potential medicinal activity, used in China as a folk medicine to regulate menstruation and prevent cancer. Nevertheless, there are few reports

Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity

ERK1/2 inhibitors have attracted special attention concerning the ability of circumventing cases of innate or log-term acquired resistance to RAF and MEK kinase inhibitors. Based on the 4-aminoquinazoline pharmacophore of kinases, herein we describe the synthesis of 4-aminoquinazoline derivatives bearing a 1,2,3-triazole stable core to bridge different aromatic and heterocyclic rings using copper-catalysed azide-alkyne cycloaddition reaction (CuAAC) as a Click Chemistry strategy. The initial screening of twelve derivatives in tumoral cells (CAL-27, HN13, HGC-27, and BT-20) revealed that the most active in BT-20 cells (25a, IC50 24.6 μM and a SI of 3.25) contains a more polar side chain (sulfone). Furthermore, compound 25a promoted a significant release of lactate dehydrogenase (LDH), suggesting the induction of cell death by necrosis. In addition, this compound induced G0/G1 stalling in BT-20 cells, which was accompanied by a decrease in the S phase. Western blot analysis of the levels of p-STAT3, p-ERK, PARP, p53 and cleaved caspase-3 revealed p-ERK1/2 and p-STA3 were drastically decreased in BT-20 cells under 25a incubation, suggesting the involvement of these two kinases in the mechanisms underlying 25a-induced cell cycle arrest, besides loss of proliferation and viability of the breast cancer cell. Molecular docking simulations using the ERK-ulixertinib crystallographic complex showed compound 25a could potentially compete with ATP for binding to ERK in a slightly higher affinity than the reference ERK1/2 inhibitor. Further in silico analyses showed comparable toxicity and pharmacokinetic profiles for compound 25a in relation to ulixertinib.